Original Article

Early Results of Ranibizumab Monotherapy in Patients with
  • Nilüfer Koçak
  • Mahmut Kaya
  • Özlem Barut Selver
  • Ziya Ayhan
  • Süleyman Kaynak
Turk J Ophthalmol 2011; 41: 10-15 DOI: 10.4274/tjo.41.03
First-Year Outcomes of Cataract Surgery Combined with Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration
  • Sabahattin Sül
  • Aylin Karalezli
  • Müjdat Karabulut
Turk J Ophthalmol 2019; 49: 15-19 DOI: 10.4274/tjo.galenos.2018.76429
Results of Intravitreal Ranibizumab Treatment for Exudative Age-Related Macular Degeneration
  • Umut Karaca
  • Ali Hakan Durukan
  • Fazil Cüneyt Erdurman
  • Güngör Sobaci
  • Mehmet Zeki Bayraktar
Turk J Ophthalmol 2012; 42: 25-29 DOI: 10.4274/tjo.42.46036
Direct Treatment Costs of Neovascular Age-related Macular Degeneration and Comparison of Gained and/or Preserved Vision with Expenditure
  • Şeyda Yıldırım
  • Cezmi Akkın
  • Zafer Öztaş
  • Serhad Nalçacı
  • Filiz Afrashi
  • Jale Menteş
Turk J Ophthalmol 2018; 48: 27-32 DOI: 10.4274/tjo.44370 PMID:29576895
Evaluation of Aflibercept Treatment Responses in Eyes with Bevacizumab/Ranibizumab-resistant Wet Age-related Macular Degeneration
  • Tuncay Topal
  • Taner Kar
  • Yıldıray Yıldırım
  • Sercan Koray Sağdıç
  • Cihan Büyükavşar
  • Abdullah Kaya
  • Ali Ayata
  • Murat Sönmez
  • Melih Hamdi Ünal
Turk J Ophthalmol 2017; 47: 133-137 DOI: 10.4274/tjo.34735 PMID:28630787
Comparison of Ranibizumab and Pegabtanib Sodium Monotherapies in Terms of Rates of Stabilization After the First Three Doses
  • Nilüfer Koçak
  • Hüseyin Aslankara
  • Durgül Türüthan
  • Süleyman Kaynak
Turk J Ophthalmol 2012; 42: 211-215 DOI: 10.4274/tjo.42.42714
Comparison of Efficacy Between anti-VEGF Agents Alone and in Combination with Photodynamic Therapy in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
  • Sunay Duman
  • Damla Ergintürk Acar
  • Güner Üney
  • Dicle Hazırolan
  • Mehmet Akif Acar
  • Nurten Ünlü
Turk J Ophthalmol 2010; 40: 343-348 DOI: 10.4274/tjo.40.343
Intravitreal Ranibizumab Therapy in Wet Type Macular Degeneration
  • Hüseyin Dündar
  • Hasan Altinkaynak
  • Can Kocasaraç
  • Leyla Hazar
  • Kemal Yüksel
Turk J Ophthalmol 2014; 44: 356-360 DOI: 10.4274/tjo.02418

Case Report

Multiple Intravitreal Ranibizumab Injections for Persistant Choroidal Neovascularization Associated with Presumed Ocular Histoplasmosis Syndrome
  • Turgut Yılmaz
  • Seyhan Dikci
  • Oğuzhan Genç
  • Kayhan Mutlu
Turk J Ophthalmol 2017; 47: 115-118 DOI: 10.4274/tjo.82956 PMID:28405488
Choroidal Osteoma and Secondary Choroidal Neovascularization Treated with Ranibizumab
  • Almila Sarigül Sezenöz
  • Sezin Akça Bayar
  • Gürsel Yılmaz
Turk J Ophthalmol 2017; 47: 243-246 DOI: 10.4274/tjo.86658 PMID:28845332

Original Article

Factors Affecting Compliance to Intravitreal Anti-Vascular Endothelial Growth Factor Therapy in Patients with Age-Related Macular Degeneration
  • Onur Polat
  • Sibel İnan
  • Serkan Özcan
  • Mustafa Doğan
  • Tuncay Küsbeci
  • Güliz Fatma Yavaş
  • Ümit Übeyt İnan
Turk J Ophthalmol 2017; 47: 205-210 DOI: 10.4274/tjo.28003 PMID:28845324
Comparison of Corneal Endothelial Changes After a Single-Dose Injection of Bevacizumab or Ranibizumab
  • Fatih Horozoğlu
  • Tansu Gönen
  • Mustafa Yaşar
  • Özkan Sever
  • Kadircan Keşkinbora
Turk J Ophthalmol 2013; 43: 391-394 DOI: 10.4274/tjo.82621